| Andrew Laughlin, PT, DPT | |
|
1828 E Florence Blvd, Casa Grande, AZ 85122-4783 | |
| (520) 510-0360 | |
| Not Available |
| Full Name | Andrew Laughlin |
|---|---|
| Gender | Male |
| Speciality | Physical Therapist - Orthopedic |
| Location | 1828 E Florence Blvd, Casa Grande, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114607363 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 2023027805 (Missouri) | Secondary |
| 2251X0800X | Physical Therapist - Orthopedic | 2023027805 (Missouri) | Primary |
| Provider Name | Bhsm Rehabilitation Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1497271431 PECOS PAC ID: 2062773138 Enrollment ID: O20180306002185 |
News Archive
Shionogi today announced that once-daily naldemedine met its primary and secondary endpoints in a phase III study (COMPOSE II) for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
The Robert Wood Johnson Foundation (RWJF) and the Plexus Institute (Plexus) today announce results from an analysis of a multifaceted methicillin-resistant Staphylococcus aureus (MRSA) prevention program that employed positive deviance (PD), a novel approach to social and behavioral change, to trigger significant reductions in MRSA incidence ranging from 26 to 62 percent at participating hospitals.
Working to further the understanding of how the brain processes information, Valentin Dragoi, Ph.D., of The University of Texas Health Science Center at Houston has been awarded a three-year, $1.6 million award from the National Institutes of Health's Brain Research through Advancing Innovative Neurotechnologies Initiative.
Johns Hopkins infectious disease specialists who have spent more than two decades leading efforts to combat HIV and AIDS worldwide are warning that limited international relief supplies of antiretroviral therapies currently being distributed in Africa, Asia and the Caribbean will not get to those who can least afford to pay for them.
The development of a safe and effective vaccine will likely be required to end the COVID-19 pandemic. A group of scientists, led by Beth Israel Deaconess Medical Center immunologist Dan H. Barouch, MD, PhD, now report that a leading candidate COVID-19 vaccine developed at BIDMC in collaboration with Johnson & Johnson raised neutralizing antibodies and robustly protected non-human primates against SARS-CoV-2, the virus that causes COVID-19.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Andrew Laughlin, PT, DPT 1611 N 58th St, Omaha, NE 68104-4821 Ph: (816) 591-5777 | Andrew Laughlin, PT, DPT 1828 E Florence Blvd, Casa Grande, AZ 85122-4783 Ph: (520) 510-0360 |
News Archive
Shionogi today announced that once-daily naldemedine met its primary and secondary endpoints in a phase III study (COMPOSE II) for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
The Robert Wood Johnson Foundation (RWJF) and the Plexus Institute (Plexus) today announce results from an analysis of a multifaceted methicillin-resistant Staphylococcus aureus (MRSA) prevention program that employed positive deviance (PD), a novel approach to social and behavioral change, to trigger significant reductions in MRSA incidence ranging from 26 to 62 percent at participating hospitals.
Working to further the understanding of how the brain processes information, Valentin Dragoi, Ph.D., of The University of Texas Health Science Center at Houston has been awarded a three-year, $1.6 million award from the National Institutes of Health's Brain Research through Advancing Innovative Neurotechnologies Initiative.
Johns Hopkins infectious disease specialists who have spent more than two decades leading efforts to combat HIV and AIDS worldwide are warning that limited international relief supplies of antiretroviral therapies currently being distributed in Africa, Asia and the Caribbean will not get to those who can least afford to pay for them.
The development of a safe and effective vaccine will likely be required to end the COVID-19 pandemic. A group of scientists, led by Beth Israel Deaconess Medical Center immunologist Dan H. Barouch, MD, PhD, now report that a leading candidate COVID-19 vaccine developed at BIDMC in collaboration with Johnson & Johnson raised neutralizing antibodies and robustly protected non-human primates against SARS-CoV-2, the virus that causes COVID-19.
› Verified 3 days ago
Kyle Flood, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 580 N Camino Mercado Ste 25, Casa Grande, AZ 85122 Phone: 855-331-7522 | |
Ari David Goldstein, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1295 E Florence Blvd Ste 1-3, Casa Grande, AZ 85122 Phone: 520-494-3058 Fax: 520-214-5059 | |
Cory C Mckinnon, P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 580 N Camino Mercado Ste 13, Casa Grande, AZ 85122 Phone: 520-836-8621 | |
Corey Shaun Brinton, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 580 N Camino Mercado Ste 13, Casa Grande, AZ 85122 Phone: 520-836-8621 | |
Trevor Dickman, Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1828 E Florence Blvd, Casa Grande, AZ 85122 Phone: 520-510-0360 | |
Dr. Eric Johnson, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 580 N Camino Mercado Ste 25, Casa Grande, AZ 85122 Phone: 855-331-7522 |